HIV-patients gain weight and muscle mass with steroids

People who are suffering from the dreaded HIV-virus and making use of anabolic steroids to prevent AIDS wasting tend to gain modest gains in terms of muscle mass and weight, according to a new review. Anabolic steroids are synthetic substances like to the masculine sex hormone testosterone that promote growth of skeletal muscle and the development of man sex characteristics. Although most recently in the news for their misuse by professional athletes, anabolic steroids have valid medical application for men with low testosterone and people with certain types of anemia. Two anabolic steroids available in the United States, nandrolone decanoate and oxandrolone, have been used to help increase weight and muscle mass in small studies of people with wasting. Conversely, anabolic steroid use has been associated with increased rates of HIV in those who share needles or use nonsterile needles when they inject steroids.

We were unable to assess these risks in our review due to the small duration of treatment in the studies. It is worth nothing that AIDS wasting results in considerable loss of cadaver weight in HIV-patients apart from muscle loss. It stems from human body’s inability to promote muscle growth and testosterone levels, which can be effectively handled with anabolic steroids.

AIDS wasting syndrome (cachexia) is a condition associated with advanced HIV disease. It involves overall weight loss, but more importantly, the loss of lean body mass, or muscle, which sometimes may be replaced by fat. Weight loss results from a number of factors, alone or in combination, including lack of appetite, nausea, diarrhea, oral problems that build eating hard, and problems related to intestinal absorption and use of nutrients. The condition was much more prevalent in the developed world before alliance antiretroviral remedy became available.

A correct diagnosis and the proper intervention for each individual are as important in treating AIDS wasting as they are for any other medical problem. Early intervention is often most successful, and a variety of effective and relatively inexpensive tools (such as nutritional supplements, appetite stimulants, and exercise) can be used. HGH is not a universal remedy for treating AIDS wasting. While it can have a dramatically beneficial effect in some individuals (presumably those with a deficiency of natural hGH), the majority may see no benefit. The current hGH regimen for AIDS wasting consists of a daily injection administered at bedtime to mimic the normal cycle of growth hormone release into the bloodstream. The portion is 4-6 mg, based upon body weight. HGH alone is likely to result in weight gain that is primarily overweight, while adding a regimen of resistance exercise, such as weight training, can help build lean cadaver mass.

The human papillomavirus and HIV positive women

HIV positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune structure is struggling, according to newly published results of an international clinical trial. The study's findings counter doubts about whether the vaccine would be helpful, said the Brown University medical professor who led the study. Instead, the data support the World Health Organization's recommendation to vaccinate women with HIV.

HPV causes cervical and other cancers. The commonly used HPV vaccine Gardasil had not been tested in seriously immune-suppressed women with HIV, said Dr. Erna Milunka Kojic, associate professor of medicine at the Warren Alpert Medical School of Brown University and The Miriam Medical centre. Despite the WHO advice, she said, skeptics have wondered whether the vaccine would be safe and helpful for women with weakened immune systems who were already likely to have been exposed to HPV through sex. Vaccines are often less effective in HIV-positive people.

To address that debate, Kojic's study, dubbed "AIDS Clinical Trials Group Protocol 5240," measured the safety and immune system response of the vaccine in HIV-positive women aged 13 to 45 with a wide range of immune statuses. In the vast majority of the 315 volunteers who were vaccinated at sites in the United States, Brazil, and South Africa, the vaccine built up antibodies against HPV and posed no unusual safety issues during the 28 weeks they were each involved.

"The vaccine works for HIV-infected women in terms of developing antibodies," Kojic said. Co-author Dr. Susan Cu-Uvin, professor of public condition and of obstetrics and gynecology at Brown, said women with HIV are especially susceptible to cervical cancer from HPV because their weakened immune systems are less able to clear the virus. That makes vaccinating HIV-positive women especially important, so long as it's safe and they respond. This is a very safe vaccine. It doesn't have any systemic side effects among these women who are already taking medicine for other conditions. To investigate that response in the context of HIV, the study grouped women by their CD4 cell count, a measure of immune system health. Group A had CD4 counts above 350, group B rested between 200 and 350. Group C was composed of women with counts below 200, the defining level of AIDS for which response to an HPV vaccine had not yet been studied.

Steroid Can Restore Body Tissue in HIV-Positive People

Of the 3 orally dynamic anabolic steroids, Oxandrolone has been studied in HIV-infected patients more extensively than has oxymetholone. Stanozolol is used for the treatment of hereditary angioedema and has not been used for its anabolic effect in this patient populace to any great extent.

One of the earlier studies of Oxandrolone in HIV-infected patients was begun before the introduction of the PIs. Sixty-three HIV-infected men with a deprivation of corpse weight greater than 10% were randomized to receive placebo, oxandrolone, 5 mg/d or Oxandrolone, 15 mg/d. The patients who received 15 mg/d of oxandrolone gained weight throughout the 16-week interval, whereas those who received 5 mg/d of oxandrolone maintained their weight. In contrast, the patients who received placebo continued to lose weight.

In a follow-up study, which has not yet been published, patients were randomized to placebo or to 1 of 3 dosages of Oxandrolone 20 mg/d, 40 mg/d, or 80 mg/d. The patients in the group who received 40 mg/d had the most statistically significant weight gain. However, both the patients in this assembly and those who received 80 mg/d showed important increases in serum levels of liver transaminases.

A study published in 1999 sought to terminate whether a regimen of supraphysiologic doses of androgen (testosterone) plus an anabolic steroid (oxandrolone) would better the LBM and strength gains achieved with advancing resistance exercise in HIV-infected men who had practised weight loss. A second objective of the study was to determine whether antiretroviral remedy with a PI prevented lean corpse anabolism.

All subjects in the study participated in supervised progressive resistance exercise for 8 weeks. At the same period, they received testosterone, 100 mg/wk, by intramuscular injection. Twenty-four eugonadal men were then randomized to either placebo or oxandrolone, 20 mg/d. Twenty-two patients completed the read. The results indicated that compared with patients who received placebo, those who received oxandrolone experienced improved nitrogen weigh (P = .05); increased LBM (P = .005) and increased muscle strength, as judged by either maximum weight lifted (P = .02 to .05) or dynamometry (P = .01 to .05). The results were like regardless of whether the patients were taking a PI. However, compared with placebo, oxandrolone was associated with a statistically significant decrease in blood levels of high-den-sity lipoprotein (HDL) cholesterol (P < .001).

Because all patients in the study participated in progressive opposition training and received testosterone, only an additive effect of Oxandrolone versus placebo was being decided. Therefore, the study appears to be valid even though the number of patients enrolled was little. On the other hand, had the design of the study called for dividing the patients into multiple groups, so that not all patients received testosterone or participated in progressive resistance exercise, the number of patients required to reach statistical significance would have been much higher on the organization of 350.

The conclusions that can be drawn from the study are that Oxandrolone 20 mg/d, added to a program consisting of both progressive resistance exercise and physiologic doses of testosterone improved the anabolic and functional responses in patients who showed HIV-related weight loss.

Only 1 study of oxymetholone in HIV-infected patients has been reported. This study was a nonblinded pilot trial that was completed in Germany and reported in 1996. Patients were randomly assigned to receive either Oxymetholone (14 patients) or Oxymetholone plus ketotifen (16 patients). Ketotifen is an H1-receptor antagonist that has been shown to block tumor necrosis factor A. The patients receiving the medications under study were compared with 30 matched control patients who met the same inclusion criteria, such as advanced HIV infection and chronic cachexia.

At entry into the study, all patients had experienced significant weight loss (greater than 12 kg [26.4 lb]). The average weight get by the patients who received Oxymetholone was 8.2 kg (18 lb), a 14.5% grow over weight at entry (P < .001). The average weight gain by the patients who received association therapy was 6.1 kg (13.4 lb), a 10.9% increase over weight at entry (P < .005). The untreated control patients lost an average of 1.8 kg (4 lb). Both groups of treated patients showed improvement in the ability to perform activities of daily living and in several quality-of-life variables. Although this study was not a double-blind clinical trial, the investigators believed that the results suggested the need for a randomized, double-blind, placebo-controlled, multicenter trial.

Risk of AIDS among athletes who use anabolic steroids

Sometimes, athletes who use anabolic steroids may share the needles, syringes or other equipment they use to introduce these drugs. By sharing needles, syringes or other equipage, a individual becomes a great danger for HIV transmission. HIV is the virus that causes AIDS.

If a person shares needles, syringes and other equipment to inject steroids into the vein (IV), in the muscles or under the skin, small amounts of blood from the individual infected with HIV may be injected into the bloodstream of the next person to use the equipment. HIV attacks the body's defense system, making the body less able to fight off infections and cancers. There's no vaccine or cure for HIV or AIDS. People who may have been exposed to HIV should be tested. If they find out they have the virus, they can start treatment early. You can't tell just be looking at someone if he or she has HIV. And, since someone can be infected with HIV for many years without having any symptoms, some people may not know they have HIV. Anyone who has ever shared a needle to shoot any drugs even once could become infected with HIV and should be tested.

The importance of exercise has become a mantra for many people, those trying to stay healthy and those with a chronic sickness - HIV included. But when you have HIV, exercise becomes an significant part of disease management. Regular exercise can help you cope with many of the common side effects caused by the ailment and the drugs you must take, says Nelson Vergel, founder of the Cadaver Positive Wellness Clinic in Houston. Exercise not only increases lean muscle mass and heart and lung function, but it also helps you "improve your self-image and mental outlook," says Vergel, co-author of Built to Survive, which examines the importance of diet and exercise in people who are HIV-certain.

Ergogenic aids are substances that some athletes use to better strength and stamina. Anabolic steroids are one class of ergogenic aid that many adults and even adolescents often employ in their efforts to improve their athletic performance and advent. According to the American College of Sports Medicine, individuals who are experienced in weight lifting and employ the use of anabolic steroids will experience increases in strength and muscle significantly beyond those from training alone. It is this need to win and get a competitive edge that drives athletes to seek a variety of ergogenic aids.

Effects of anabolic steroids:
Anabolic steroids, favourite among athletes and corpse-builders, increase muscle mass. A variety of types are combined in a procedure called "stacking," which athletes use to gain the best attributes from each particular medication. "Blood doping" increases red blood cell content, which improves muscular stamina. Red blood cells transport oxygen to the working muscles. Obtaining a higher percentage of transport vehicles allows the muscles to work harder and for a longer duration without weariness. Some pharmacological drugs such as beta blockers can be used to reduce anxiety and tremors. This is useful for individuals competing in sports that require smooth, focused movements, such as archery or shooting.

Aids in haemophiliacs and steroids treatment

Aids in haemophiliacs is clearly related to the use of corticosteroids and other immunosuppressive agents used to prevent the development of antibodies to factors VIII and IX, and to treat chronic illnesses. In his textbook, Dr Fauci and his co-authors note that haemophiliac patients routinely receive immunosuppressive drugs as part of their treatment. Patients with severe haemophilia have serious chronic joint problems resulting from bleeding inside the joints. This is invariably treated with steroids. Many haemophiliacs with Aids are HIV-negative.  Aids in people receiving blood and tissue is related to the use of glucocorticoids to prevent the adverse reactions caused by transfusion and tissue rejection. Again, it is standard treatment to give such patients steroids.

Aids in infants and children is probably a result of their exposure to street drugs or steroids in utero and, after birth, to steroids used to treat their chronic illnesses. For instance, mothers expected to have a premature birth are routinely treated with steroids - a standard procedure since the 1970s. In premature babies, steroids are used to help develop the lungs and to reduce the incidence of necrotising enterocolitis (inflammation and ulceration of the bowel associated with shock, impaired blood flow or antibiotic therapy). In addition, the natural cortisol levels in the plasma and urine of preterm babies exposed to cocaine is significantly higher than that of unexposed infants.

The anti-HIV drugs

The anti-HIV drugs d4T and AZT are not recommended for procedure treatment if you have other treatment options available. Slow fat gain in the limbs has been seen in people who switched from d4T to tenofovir (Viread).

A number of treatments for corpse fat changes are being deliberate including human development hormone, anabolic steroids, appetite stimulants, and heaviness training.

In extreme cases, fat deposits at the back of the neck may be surgically removed. Several forms of surgery have been used to repair facial fat changes, and New Fill is becoming increasingly available at NHS HIV clinics.

High blood fats may be treated with drugs such as pravastatin or gemfibrozil, and insulin resistance with anti-diabetes drugs. Some statins can interact with some HIV drugs, so your doctor will choose your drugs with anxiety and monitor you closely. There are also things you can do yourself. As noted above, routine exercise, a satisfactory nutriment with lots of new fruit and vegetable, and stopping smoking can all help reduce your danger of nerve affliction.

Treatment with testosterone

There has been much argument about the part of testosterone levels in AIDS wasting. Testosterone is the man hormone which promotes muscle growth. Following the inspection of low levels of serum testosterone in many men with AIDS wasting, a stipulation known as hypogonadism, some treatment advocates and doctors have argued that correcting the testosterone deficiency may reverse wasting.

However, the relationship between HIV infection, testosterone production and AIDS wasting is still unclear. One recent study found no relationship between wasting and hypogonadism, but a review of patients in the Multi center AIDS Cohort Study (MACS), a large United States cohort followed since 1985, found that testosterone levels fell before the onset of wasting. A study of testosterone levels in women with AIDS wasting found that more than half the women had low levels of testosterone. Symptoms of testosterone deficiency comprise fatigue, reduced sex make, infertility, depression and deprivation of appetite.

These symptoms are common in advanced HIV disease, and may be associated with many other illnesses and malnutrition. Testosterone levels are reduced in chronic illnesses as an adaptive measure to conserve vitality. Even when effective antiretroviral treatment reduces HIV levels and clears up opportunistic infections, some experts suggest that testosterone levels will not return to standard on their own. Opportunistic infections can also lead to hypogonadism.
Testosterone injections or derma patches that deliver testosterone on a daily basis are being investigated as a way of maintaining testosterone levels, and some controlled studies have investigated the effectiveness of various testosterone preparations in encouraging the replacement of lean muscle tissue. A randomized, controlled, double-blind trial of testosterone injections establish that men who received testosterone gained muscle and weight, and reported feeling better in comparison to men who received placebo. However, benefits seem to be restricted to men with hypogonadism.